Located in Santa Clara, California the company was founded in January 2004 to develop a radically new technology for the treatment of ocular disease. Initially developed at Stanford University, and exclusively licensed to the OptiMedica Corporation, the PASCAL^® Method of Photocoagulation is used to treat a variety of retinal conditions including diabetic retinopathy, age-related macular degeneration, and retinal vascular occlusive disease. The PASCAL Photocoagulator provides significantly improved performance for the physician and an enhanced therapeutic experience for the patient.

The OptiMedica team is composed of seasoned professionals with experience in the design, development, production, marketing, and sales of medical laser devices. OptiMedica is assisted by a Medical Advisory Board composed of thought leaders in retinal disease treatment. The company received FDA clearance for its PASCAL Photocoagulator device in 2005 and secured funding from Kleiner, Perkins, Caufield & Byers and Alloy Venture Partners in the same year.